Dr. Marcus Conrad is director of the Institute of Metabolism and Cell Death at the Helmholtz Zentrum München in the field of metabolic cell death signaling and drug discovery.
His research interests lie in the field of the study of redox-regulated cell fate decisions.
Dr. Conrad generated the first mouse models with conditional knockout of the main mammalian redox-enzymes, allowing him to discover a previously uncharacterized cell death modality, now known as ferroptosis.
His current work is focused on studying the molecular mechanisms of ferroptosis as the basis for the development of novel therapies to combat difficult-to-treat diseases such as neurodegeneration and cancer.
In addition, he is developing novel ferroptosis modulating drugs, of which some have entered preclinical development for the treatment of ischemia-reperfusion-related tissue injuries, such as organ transplantation and ischemic stroke.
He has published more than 130 scientific articles and book chapters, which have received more than 18000 citations meanwhile.
Dr. Marcus Conrad holds several patents and is co-founder and shareholder of ROSCUE Therapeutics GmbH.